Sihuan Pharmaceutical Holdings Group Management
Management criteria checks 4/4
Sihuan Pharmaceutical Holdings Group's CEO is Weicheng Guo, appointed in Oct 2014, has a tenure of 10.17 years. total yearly compensation is CN¥3.00M, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth HK$7.49M. The average tenure of the management team and the board of directors is 2.2 years and 8.8 years respectively.
Key information
Weicheng Guo
Chief executive officer
CN¥3.0m
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 10.2yrs |
| CEO ownership | 0.1% |
| Management average tenure | 2.2yrs |
| Board average tenure | 8.8yrs |
Recent management updates
Recent updates
What Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 25% Share Price Gain Is Not Telling You
Oct 02
Is Sihuan Pharmaceutical Holdings Group (HKG:460) Using Too Much Debt?
Sep 30Here's Why It's Unlikely That Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO Will See A Pay Rise This Year
May 31Investors Still Waiting For A Pull Back In Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
May 27A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Dec 05Health Check: How Prudently Does Sihuan Pharmaceutical Holdings Group (HKG:460) Use Debt?
Oct 31Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Aug 19Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Apr 21Is Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Worth HK$0.8 Based On Its Intrinsic Value?
Nov 03Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?
Oct 11Is There An Opportunity With Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 34% Undervaluation?
Jun 21Estimating The Intrinsic Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Mar 09A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Nov 28Sihuan Pharmaceutical Holdings Group (HKG:460) Seems To Use Debt Rather Sparingly
Sep 26We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO For Now
Jun 22How Does Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Fare As A Dividend Stock?
May 11Sihuan Pharmaceutical Holdings Group's (HKG:460) Shareholders May Want To Dig Deeper Than Statutory Profit
Mar 30How Much Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Do Insiders Own?
Mar 07Should You Buy Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) For Its Dividend?
Feb 07
Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Jan 11Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?
Dec 21Why Sihuan Pharmaceutical Holdings Group's (HKG:460) CEO Pay Matters
Dec 07CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -CN¥38m |
| Mar 31 2024 | n/a | n/a | -CN¥46m |
| Dec 31 2023 | CN¥3m | CN¥3m | -CN¥54m |
| Jun 30 2023 | n/a | n/a | -CN¥2b |
| Mar 31 2023 | n/a | n/a | -CN¥2b |
| Dec 31 2022 | CN¥3m | CN¥3m | -CN¥2b |
| Jun 30 2022 | n/a | n/a | -CN¥144m |
| Mar 31 2022 | n/a | n/a | CN¥141m |
| Dec 31 2021 | CN¥6m | CN¥6m | CN¥427m |
| Sep 30 2021 | n/a | n/a | CN¥681m |
| Jun 30 2021 | n/a | n/a | CN¥945m |
| Mar 31 2021 | n/a | n/a | CN¥727m |
| Dec 31 2020 | CN¥6m | CN¥6m | CN¥508m |
| Sep 30 2020 | n/a | n/a | -CN¥14m |
| Jun 30 2020 | n/a | n/a | -CN¥537m |
| Mar 31 2020 | n/a | n/a | -CN¥2b |
| Dec 31 2019 | CN¥6m | CN¥6m | -CN¥3b |
| Sep 30 2019 | n/a | n/a | -CN¥2b |
| Jun 30 2019 | n/a | n/a | -CN¥1b |
| Mar 31 2019 | n/a | n/a | CN¥238m |
| Dec 31 2018 | CN¥6m | CN¥6m | CN¥2b |
| Sep 30 2018 | n/a | n/a | CN¥1b |
| Jun 30 2018 | n/a | n/a | CN¥1b |
| Mar 31 2018 | n/a | n/a | CN¥1b |
| Dec 31 2017 | CN¥6m | CN¥6m | CN¥1b |
Compensation vs Market: Weicheng's total compensation ($USD411.03K) is about average for companies of similar size in the Hong Kong market ($USD479.63K).
Compensation vs Earnings: Weicheng's compensation has been consistent with company performance over the past year.
CEO
Weicheng Guo (60 yo)
10.2yrs
Tenure
CN¥3,000,000
Compensation
Dr. Weicheng Guo co-founded Sihuan Pharmaceutical Holdings Group Ltd. and has been its Chief Executive Officer since October 20, 2014. Dr. Guo is responsible for the overall operations of Sihuan Pharmaceut...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 18.6yrs | CN¥7.00m | 5.34% HK$ 328.3m | |
| Deputy Chairman & CEO | 10.2yrs | CN¥3.00m | 0.12% HK$ 7.5m | |
| Deputy CEO | 2.2yrs | CN¥5.05m | no data | |
| Executive Director | 4.1yrs | CN¥646.00k | 2.14% HK$ 131.3m | |
| Joint Company Secretary & Executive Director | 2.2yrs | CN¥1.77m | no data | |
| Joint Company Secretary | 2.2yrs | no data | no data | |
| Deputy General Manager | no data | CN¥4.26m | no data |
2.2yrs
Average Tenure
60yo
Average Age
Experienced Management: 460's management team is considered experienced (2.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 18.6yrs | CN¥7.00m | 5.34% HK$ 328.3m | |
| Deputy Chairman & CEO | 18.6yrs | CN¥3.00m | 0.12% HK$ 7.5m | |
| Deputy CEO | 2.2yrs | CN¥5.05m | no data | |
| Executive Director | 6.7yrs | CN¥646.00k | 2.14% HK$ 131.3m | |
| Joint Company Secretary & Executive Director | 6.7yrs | CN¥1.77m | no data | |
| Independent Non-Executive Director | 11.3yrs | CN¥371.00k | no data | |
| Independent Non-Executive Director | 10.8yrs | CN¥371.00k | no data | |
| Independent Non-Executive Director | 1.7yrs | CN¥202.00k | no data |
8.8yrs
Average Tenure
61yo
Average Age
Experienced Board: 460's board of directors are considered experienced (8.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 09:40 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sihuan Pharmaceutical Holdings Group Ltd. is covered by 24 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shaojing Tong | BofA Global Research |
| Harry He | China Galaxy International Securities (Hong Kong) |
| Sze Chuen Tam | Core Pacific -Yamaichi International (H.K.) Limited |